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Abstract: Background. The prevalence of heart failure with preserved ejection fraction (HFpEF) in
patients with antiphospholipid syndrome (APS) is unknown. Methods. A prospective multicenter
cohort study including 125 patients was conducted: 91 primary APS (PAPS), 18 APS-SLE, and
16 carriers. HFpEF was diagnosed according to the 2019 European Society of Cardiology criteria:
patients with ≥5 points among major and minor functional and morphological criteria including NT-
ProBNP > 220 pg/mL, left atrial (LA) enlargement, increased left ventricular filling pressure. Results.
Overall, 18 (14.4%) patients were diagnosed with HFpEF; this prevalence increased from 6.3% in
carriers to 13.2% in PAPS and 27.8% in APS-SLE. Patients with HFpEF were older and with a higher
prevalence of hypertension and previous arterial events. At logistic regression analysis, age, arterial
hypertension, anticardiolipin antibodies IgG > 40 GPL (odds ratio (OR) 3.43, 95% confidence interval
(CI) 1.09–10.77, p = 0.035), anti β-2-glycoprotein-I IgG > 40 GPL (OR 5.28, 1.53–18.27, p = 0.009), lupus
anticoagulants DRVVT > 1.25 (OR 5.20, 95% CI 1.10–24.68, p = 0.038), and triple positivity (OR 3.56,
95% CI 1.11–11.47, p = 0.033) were associated with HFpEF after adjustment for age and sex. By
multivariate analysis, hypertension (OR 19.49, 95% CI 2.21–171.94, p = 0.008), age (OR 1.07, 95% CI
1.00–1.14, p = 0.044), and aβ2GPI IgG > 40 GPL (OR 8.62, 95% CI 1.23–60.44, p = 0.030) were associated
with HFpEF. Conclusion. HFpEF is detectable in a relevant proportion of APS patients. The role of
aPL in the pathogenesis and prognosis of HFpEF needs further investigation.
Keywords: antiphospholipid syndrome; HFpEF; echocardiography; heart failure
1. Introduction
Antiphospholipid syndrome (APS) is an autoimmune disorder including a wide
range of conditions ranging from seronegative APS to primary APS (PAPS) and secondary
systemic lupus erythematosus-associated APS (APS-SLE) [1]. APS is characterized by a sig-
nificant morbidity and mortality, which are not prevented by current treatments [2,3]. Thus,
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an increased risk of venous and arterial vascular thrombotic events has been described
despite oral anticoagulant treatment [4–6].
In addition to thrombotic complications, patients with APS may also have cardiac
abnormalities, including systolic and diastolic dysfunction, which may be present both in
patients with PAPS and APS-SLE [7,8]. In accordance, previous data suggested that heart
failure (HF) may be one of the clinical manifestation of APS, but this evidence relies on
small case series [9].
The N-terminal ProBNP (NT-ProBNP) is widely used for the diagnosis and monitoring
of HF, and its plasma levels bear prognostic value [10]. An NT-ProBNP-guided patient
management was associated with a lower incidence of cardiovascular events compared to
standard of care [11].
The combined use of NT-ProBNP and echocardiography data allows a better char-
acterization of HF phenotypes [12]. In particular, a previously unrecognized group of
patients is represented by the so-called HF with preserved ejection fraction (HFpEF). These
patients have a preserved left ventricular (LV) ejection fraction (EF) > 50%, with an in-
creased level of NT-ProBNP and echocardiography evidence of structural heart disease,
including left atrial (LA) enlargement and increased LV filling pressure [12]. The natural
history of patients with HFpEF is complicated by a remarkably high incidence of cardio-
vascular complications [13]. Thus, the rate of total hospitalizations for heart failure and
death from cardiovascular causes in the PARAGON-HF trial ranged from 12.8 to 14.6 per
100 patient-years [14].
Levels of NT-ProBNP as well as prevalence of HFpEF in patients with APS have never
been reported.
To this aim, we investigated the presence of HFpEF in a cohort of consecutive patients
with APS.
2. Materials and Methods
We derived our data from a multicenter ongoing prospective cohort study including
consecutive APS patients from four centers: (1) Atherothrombosis Center of Department of
Clinical Internal, Anesthesiologic and Cardiovascular Sciences of Sapienza University of
Rome, (2) Fondazione APS—Anticorpi Antifosfolipidi ONLUS, Naples, (3) Centro Emostasi
A.O.R.N. “SG Moscati”, Avellino, and (4) Division of Allergy and Clinical Immunology,
University of Salerno, all in Italy. We included patients with confirmed diagnosis of APS by
anticardiolipin (aCL), anti β-2-glycoprotein-I (aβ2GPI), or lupus anticoagulant (LAC) [15].
We also included a control group of patents with antiphospholipid antibody (aPL) but
without thrombotic events (carriers group).
Exclusion criteria were active cancer or history/treatment with cardiotoxic drugs,
history of myocardial infarction, or heart failure with reduced ejection fraction (HFrEF).
The diagnosis of diabetes [16], arterial hypertension [17], previous myocardial infarc-
tion [18], and HFrEF [12] were made according to the current international guidelines.
3. NT-ProBNP Measurement
NT-ProBNP levels were detected at baseline in all patients using a sandwich ELISA
technology kit (FineTest®). Values were expressed as pg/mL. Intra- and inter-assay coeffi-
cients of variation were <8% and <10%, respectively.
4. Transthoracic Echocardiography
All resting transthoracic echocardiography exams were performed at baseline in left
lateral decubitus with sequential analysis of the parasternal, apical, suprasternal, and
subxiphoid windows. Echocardiographic parameters were assessed in conformity with the
recommendations of the American Society of Echocardiography (ASE) [19]. The same two
operators performed echocardiography examinations in all centers (DP, TB).
We collected the following echocardiographic parameter: diastolic interventricular
septum (IVS) and posterior wall, LV diastolic diameter volume indexed to body surface area
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(BSA), relative wall thickness (RWT), LV mass (LVM)/BSA, LV ejection fraction (Simpson’s
method), right ventricle diameter, LA diameter, LA area, LA volume/BSA, pulsed Doppler
analysis of mitral flow (E wave, A wave, E/A ratio), lateral and septal mitral annular
tissue Doppler (e’septal, e´lateral), and E/e´ratio. According to LVM/BSA and RWT, we
classified LV geometry as (1) normal LV geometry, (2) concentric remodeling, (3) concentric
hypertrophy, (4) eccentric hypertrophy.
The presence of HFpEF was diagnosed according to the 2019 consensus recommenda-
tion from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
Thus, patients with ≥5 points as the sum of major and minor criteria were diagnosed with
HFpEF [20].
5. Ethical Statement
The study was conducted according to the principles embodied in the Declaration of
Helsinki and was approved by local ethical board of Sapienza University of Rome (Ref:
4417, 2 March 2017). All patients provided written informed consent.
6. Statistical Analysis
Categorical variables were reported as counts (percentage); continuous variables were
expressed as mean ± standard deviation. Independence of categorical variables was tested
with the χ2 test. Student’s unpaired t tests and ANOVA tests were used to compare means.
A first descriptive analysis of clinical and echocardiography characteristics according to aPL
status, such as PAPS, APS-SLE, and carriers was performed. Then, patients were divided
in two groups according to the presence or not of HFpEF. Univariable and multivariable
logistic regression analysis were used to calculate the relative odds ratio (OR) and 95%
confidence interval (95% CI) for each factor associated with the diagnosis of HFpEF. Only
variables associated with HFpEF after adjustment for age and sex were inserted in the
multivariable logistic regression analysis model. Only p values < 0.05 were considered as
statistically significant. Analysis was performed using SPSS-25.0, SPSS Inc.
7. Results
The study included 130 consecutive patients with aPL; of these, 4 were excluded as
presenting with HFrEF and 1 for missing data. Thus, the final cohort was composed of
125 patients: 91 primary APS, 18 APS-SLE, and 16 carriers. Previous arterial events were
recorded in 39 patients: 30 stroke and 9 peripheral artery thrombosis. Previous VTE were
recorded in 74 patients: 70 deep vein thrombosis/pulmonary embolism, 2 splanchnic vein
thrombosis, and 2 cerebral vein thrombosis. Characteristics of patients are listed in Table 1.
Patients with APS-SLE were more frequently women, with a higher prevalence of
hypertension and diabetes compared to the other groups (Table 1). Previous VTE was
more frequent in PAPS patients, while APS-SLE patients had higher prevalence of arterial
ischemic events (Table 1).
Characteristics of Patients with HFpEF
In the whole cohort, 18 (14.4%) patients had HFpEF. Patients with HFpEF were more
frequently affected by APS-SLE, older with a higher prevalence of previous arterial events
(Table 2). Regarding auto-antibodies, a higher prevalence of aCL IgG > 4 0 GPL (64.7% vs.
37.7%, p = 0.036), aβ2GPI IgM > 40 MPL (29.4% vs. 10.5%, p = 0.032), and IgG > 40 GPL
(64.7% vs. 37.1%, p = 0.032), as well as a LAC DRVVT > 1.25 (88.2% vs. 61.3%, p = 0.031)
was present in patients with HFpEF compared to those without, respectively (Table 2). A
trend towards a higher prevalence of triple positivity in HFpEF patients was found.
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Table 1. Characteristics of patients according to aPL status.
PAPS (n = 91) APS-SLE (n = 18) Carriers (n = 16) p among Groups
Age (years) 51.4 ± 14.0 52.2 ± 14.8 47.2 ± 14.1 0.501 #
Women (%) 60 (65.9) 16 (88.9) 13 (81.3) 0.092 §
Hypertension (%) 42 (46.2) 14 (77.8) 4 (25.0) 0.007 §
Diabetes (%) 3 (3.3) 3 (16.7) 0 (0.0) 0.033 §
Smoking (%) 21 (23.1) 2 (11.1) 1 (6.3) 0.185 §
Previous arterial events (%) 31 (34.1) 8 (44.4) 0 (0.0) 0.011 §
Previous VTE (%) 65 (71.4) 9 (50.0) 0 (0.0) <0.001 §
HFpEF (%) 12 (13.2) 5 (27.8) 1 (6.3) 0.167 §
NT-ProBNP (pg/mL) 455.9 ± 118.6 * 537.1 ± 116.0 ** 288.2 ± 41.0 <0.001 #
Treatments
Hydroxychloroquine (%) 13 (14.3) 8 (44.4) 5 (31.3) 0.009 §
Proton pump inhibitors (%) 23 (25.3) 11 (61.1) 4 (25.0) 0.009 §
Corticosteroids (%) 12 (13.2) 14 (77.8) 5 (31.3) <0.001 §
Antiplatelet drugs (%) 18 (19.8) 3 (16.7) 8 (50.0) 0.024 §
Oral anticoagulants (%) 60 (65.9) 10 (55.6) 0 (0.0) <0.001 §
Statins (%) 20 (22.0) 0 (0.0) 2 (12.5) 0.069 §
ACEi/ARBs (%) 33 (36.3) 10 (55.6) 3 (18.8) 0.083 §
Beta blockers (%) 21 (23.1) 6 (33.3) 2 (12.5) 0.356 §
Calcium channel blockers (%) 8 (8.9) 6 (33.3) 0 (0.0) 0.004 §
Diuretics (%) 17 (18.7) 2 (11.1) 2 (12.5) 0.651 §
Autoantibodies
aCL IgG > 40 GPL (%) 41 (46.1) 6 (33.3) 4 (25.0) 0.217 §
aCL IgM > 40 MPL (%) 15 (16.9) 3 (16.7) 4 (25.0) 0.728 §
aβ2GPI IgG > 40 GPL (%) 36 (40.9) 8 (44.4) 6 (37.5) 0.919 §
aβ2GPI IgM > 40 MPL (%) 11 (12.5) 2 (11.1) 3 (18.8) 0.764 §
LAC DRVVT > 1.25 (%) 66 (74.2) 12 (66.7) 2 (12.5) <0.001 §
Triple positivity (%) 41 (46.1) 6 (33.3) 1 (6.3) 0.009 §
Echocardiography measurements
Ejection fraction (%) 60.1 ± 7.2 56.9 ± 6.3 61.7 ± 6.1 0.122 #
LVED volume/BSA (mL/m2) 53.1 ± 13.2 54.7 ± 9.8 52.7 ± 9.7 0.881 #
LVM/BSA (g/m2) 81.2 ± 22.9 80.7 ± 20.3 77.7 ± 28.5 0.861 #
Normal LV geometry (%) 54.4 55.6 68.8
0.929 §
Concentric remodeling (%) 25.6 22.2 18.8
Concentric hypertrophy (%) 8.9 5.6 6.3
Eccentric hypertrophy (%) 11.1 16.7 6.3
LA diameter (mm) 35.9 ± 5.9 38.8 ± 6.6 32.7 ± 4.4 0.012 #
LA area (cm2) 18.9 ± 4.3 20.3 ± 6.2 17.2 ± 3.5 0.166 #
LA volume/BSA (mL/m2) 28.7 ± 8.6 32.7 ± 12.8 22.9 ± 7.4 0.010 #
E/A ratio 1.22 ± 0.49 1.04 ± 0.32 1.25 ± 0.48 0.359 #
e’ septal 0.09 ± 0.03 0.09 ± 0.02 0.10 ± 0.02 0.543 #
e’ lateral 0.11 ± 0.04 0.11 ± 0.04 0.11 ± 0.03 0.947 #
Mean E/e’ ratio 7.80 ± 2.49 9.09 ± 3.27 7.35 ± 1.27 0.103 #
# ANOVA test; § chi squared test; * p = 0.006 vs. carriers; ** p < 0.001 vs. carriers. ACEi: angiotensin-converting enzyme inhibitors;
APS: antiphospholipid syndrome; ARBs: angiotensin receptor blockers; aβ2GPI: anti beta-2-glycoprotein-I antibody; aCL: anticardiolipin
antibody; BSA: body surface area; DRVVT: dilute Russel’s viper venom time; HFpEF: heart failure with preserved ejection fraction; LA: left
atrium; LAC: lupus anticoagulant; LVED: left ventricular end-diastolic; LVM: left ventricular mass; PAPS: primary APS; SLE: systemic
lupus erythematosus; VTE: venous thromboembolism.
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Table 2. Characteristics of patients according to the presence of heart failure with preserved ejection fraction (HFpEF).
HFpEF No (n = 107) HFpEF Yes (n = 18) p among Groups
PAPS (%) 79 (73.8) 12 (66.7)
0.167 §APS-SLE (%) 13 (12.1) 5 (27.8)
Carriers (%) 15 (14.0) 1 (5.6)
Age (years) 49.8 ± 14.3 58.3 ± 10.1 0.017 #
Women (%) 79 (73.8) 10 (55.6) 0.113 §
Hypertension (%) 43 (40.2) 17 (94.4) <0.001
Diabetes (%) 4 (3.7) 2 (11.1) 0.176 §
Smoking (%) 21 (19.6) 3 (16.7) 0.768 §
Previous arterial events (%) 29 (27.1) 10 (55.6) 0.016 §
Previous VTE (%) 67 (62.6) 7 (38.9) 0.058 §
Treatments
Hydroxychloroquine (%) 19 (17.8) 7 (38.9) 0.041 §
Proton pump inhibitors (%) 31 (29.0) 7 (38.9) 0.397 §
Corticosteroids (%) 24 (22.4) 7 (38.9) 0.135 §
Antiplatelet drugs (%) 23 (21.5) 6 (33.3) 0.271 §
Oral anticoagulants (%) 61 (57.0) 9 (50.0) 0.579 §
Statins (%) 17 (15.9) 5 (27.8) 0.220 §
ACEi/ARBs(%) 34 (31.5) 12 (66.7) 0.005 §
Beta blockers (%) 17 (15.9) 12 (66.7) <0.001 §
Calcium channel antagonists (%) 9 (8.5) 5 (27.8) 0.017 §
Diuretics (%) 14 (13.1) 7 (38.9) 0.007 §
Autoantibodies
aCL IgG > 40 GPL (%) * 40 (37.7) 11 (64.7) 0.036 §
aCL IgM > 40 MPL (%) * 18 (17.0) 4 (23.5) 0.513 §
aβ2GPI IgG > 40 GPL (%) * 39 (37.1) 11 (64.7) 0.032 §
aβ2GPI IgM > 40 MPL (%) * 11 (10.5) 5 (29.4) 0.032 §
LAC DRVVT > 1.25 (%) * 65 (61.3) 15 (88.2) 0.031 §
Triple positivity (%) * 38 (35.8) 10 (58.8) 0.071 §
Echocardiography measurements
Ejection fraction (%) 60.7 ± 6.4 55.1 ± 8.6 0.001 #
LVED volume/BSA (mL/m2) 52.1 ± 12.1 60.1 ± 11.7 0.011 #
LVM/BSA (g/m2) 75.7 ± 18.8 109.8 ± 26.1 <0.001 #
Normal LV geometry (%) 59.8 35.3
<0.001 §
Concentric remodeling (%) 26.2 11.8
Concentric hypertrophy (%) 7.5 11.8
Eccentric hypertrophy (%) 6.5 41.2
LA diameter (mm) 34.6 ± 5.3 43.4 ± 4.1 <0.001 #
LA area (cm2) 17.7 ± 3.6 25.3 ± 3.8 <0.001 #
LA volume/BSA (mL/m2) 26.3 ± 7.6 40.9 ± 9.1 <0.001 #
E/A ratio 1.22 ± 0.48 1.06 ± 0.40 0.184 #
e’ septal 0.09 ± 0.03 0.07 ± 0.01 <0.001 #
e’ lateral 0.12 ± 0.04 0.08 ± 0.02 <0.001 #
Mean E/e’ ratio 7.22 ± 1.86 11.91 ± 2.07 <0.001 #
# Student t test; § chi squared test; * missing in 1 patient in each group. See Table 1 for abbreviations.
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By logistic regression analysis (Table 3), age, hypertension, aCL IgG > 40 GPL (OR
3.43, 95% CI 1.09–10.77, p = 0.035), aβ2GPI IgG > 40 GPL (OR 5.28, 1.53–18.27, p = 0.009),
LAC DRVVT > 1.25 (OR 5.20, 95% CI 1.10–24.68, p = 0.038), and triple positivity (OR 3.56,
95% CI 1.11–11.47, p = 0.033) were associated with HFpEF after adjustment for age and sex.
Table 3. Logistic regression analysis of factors associated with heart failure with preserved ejection fraction.








APS-SLE * 5.93 0.56–63.07 0.140
Age Univariable 1.05 1.01–1.09 0.020




Female sex 0.37 0.12–1.08 0.067
Hypertension
Univariable 25.3 3.3–197.2 0.002
Sex and age-adjusted 20.0 2.4–166.7 0.006
Diabetes
Univariable 3.22 0.54–19.03 0.197
Sex and age-adjusted 1.81 0.29–11.16 0.522
Smoking
Univariable 0.82 0.22–3.09 0.768
Sex and age-adjusted 0.92 0.23–3.64 0.903
Previous arterial events
Univariable 3.36 1.21–9.35 0.020
Sex and age-adjusted 2.67 0.91–7.83 0.074
Previous VTE
Univariable 0.38 0.14–1.06 0.064
Sex and age-adjusted 0.37 0.13–1.08 0.068
aCL IgG > 40 GPL
Univariable 3.03 1.04–8.81 0.042
Sex and age-adjusted 3.43 1.09–10.77 0.035
aCL IgM > 40 MPL
Univariable 1.50 0.44–5.15 0.515
Sex and age-adjusted 1.21 0.33–4.42 0.772
aβ2GPI IgG > 40 GPL
Univariable 3.10 1.06–9.05 0.038
Sex and age-adjusted 5.28 1.53–18.27 0.009
aβ2GPI IgM > 40 MPL
Univariable 3.56 1.06–12.01 0.041
Sex and age-adjusted 2.64 0.72–9.67 0.144
LAC DRVVT > 1.25
Univariable 4.73 1.03–21.77 0.046
Sex and age-adjusted 5.20 1.10–24.68 0.038
Triple positivity
Univariable 2.56 0.90–7.26 0.078
Sex and age-adjusted 3.56 1.11–11.47 0.033
* Carriers as reference group. APS: antiphospholipid syndrome; aβ2GPI: anti beta-2-glycoprotein-I antibody; aCL: anticardiolipin antibody;
DRVVT: dilute Russel’s viper venom time; LAC: lupus anticoagulant; PAPS: primary APS; SLE: systemic lupus erythematosus; VTE: venous
thromboembolism.
To better understand the relationship between the variables significantly associated
with HFpEF, we performed a multivariate logistic regression analysis (Table 4). In this
model, hypertension (OR 19.49, 95% CI 2.21–171.94, p = 0.008), age (OR 1.07, 95% CI
1.00–1.14, p = 0.044), and aβ2GPI IgG > 40 GPL (OR 8.62, 95% CI 1.23–60.44, p = 0.030) were
associated with HFpEF.
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Table 4. Multivariate logistic regression analysis of factors associated with heart failure with pre-
served ejection fraction.
Odds Ratio 95% CI p Value
Age 1.07 1.00–1.14 0.044
Female sex 0.50 0.13–1.85 0.298
Arterial hypertension 19.49 2.21–171.94 0.008
aβ2GPI IgG > 40 GPL 8.62 1.23–60.44 0.030
aCL IgG > 40 GPL 0.65 0.11–3.96 0.640
LAC DRVVT > 1.25 2.57 0.43–15.26 0.298
aβ2GPI: anti beta-2-glycoprotein-I antibody; aCL: anticardiolipin antibody; DRVVT: dilute Russel’s viper venom
time; LAC: lupus anticoagulant.
8. Discussion
This is the first study investigating the prevalence and correlates of HFpEF in APS.
Our study shows a clinically relevant prevalence of HFpEF in patients with APS; thus, in a
middle-aged cohort of patients, the prevalence of HFpEF increased from 6.3% in carriers to
13.2% in PAPS and to 27.8% in APS-SLE.
Patients with HFpEF were older than those without, and the majority suffered arterial
hypertension. The association between hypertension and HFpEF has been previously
recognized, given that hypertension is the main determinant of increased LV filling pres-
sure and diastolic dysfunction, which is a major criteria for the diagnosis of HFpEF [21].
Furthermore, the intense management of blood pressure was shown to reduce the incidence
of HFpEF [22].
Regarding auto-antibodies profile, we found a higher proportion of increased aCL
IgG, aβ2GPI IgG, and LAC positivity in the group of patients with HFpEF. This association
is novel and suggest that APS patients may have an early cardiac involvement represented
by the HFpEF. Our results provide new insight into the association between aPL and car-
diovascular disease. A previous metanalysis showed an increased risk of recurrent events
in patients with MI and antiphospholipid antibodies [23], and a recent work reported a
prevalence of APS in 15.5% of patients with myocardial infarction and non-obstructive
coronary arteries [24]. The association between aPL and HFpEF suggests that aPL may
contribute to the microvascular endothelial dysfunction that characterizes the pathogenesis
of HFpEF [21]. Of interest, age, IgG aβ2GPI > 40 GPL, and hypertension were indepen-
dently associated with HFpEF. Elevated IgG aβ2GPI directly relates to endothelin-1 [25]
and to isoprostane [26], two powerful vasoactive agents, and inversely relates to nitric
oxide metabolites [27], leading to increased vasomotor tone and arterial hypertension. The
release of reactive oxygen species mediated by aPL is responsible for increased oxidative
stress [28], lipid peroxidation [29], loss of the biological activity of nitric oxide [30], and
aPL modifications [31], all factors that contribute to the endothelial dysfunction status that
characterize hypertension [32] and HFpEF [33]. The potential role of oxidative stress in
HFpEF is also indirectly suggested by interventional studies with antioxidant compounds,
showing an improvement in diastolic [34] and endothelial function [35,36].
In addition, a higher proportion of triple positivity was found in HFpEF patients, indi-
cating increased potential thrombogenicity [37] in patients with HFpEF, as triple positive
patients have been shown to have an increased risk of thrombotic events compared to those
with single or double aPL positivity [38].
Remarkably, also 6.3% of aPL carriers were diagnosed with HFpEF. The potential
usefulness of preventive therapeutic strategy with aspirin or anti-hypertensive drugs in
this subgroup of subjects warrants further investigation.
Indeed, implications of our findings are that patients with aβ2GPI IgG > 40 and triple
positivity should undergo a strict cardiology follow-up to early detect the onset of HFpEF,
as this subgroup of patients may have a worse prognosis.
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The limitations of this study include the observational design and the relatively small
sample size that prevents us from drawing definite conclusion. Therefore, our results are
to be regarded as hypothesis generating. Furthermore, there are several clinical issues that
need to be addressed, such as the prognostic role of HFpEF in PAPS and APS-SLE patients,
as well as the role of different aPL types in patients diagnosed with HFpEF.
However, the identification of HFpEF may help to refine the heterogenous clinical
phenotypes of APS patients [39,40], potentially identifying those at higher risk of cardio-
vascular events.
In conclusion, a considerable proportion of patients with APS may have HFpEF. Long
term studies to investigate the impact of HFpEF on cardiovascular outcomes in these
patients are needed.
Author Contributions: D.P.: Writing—Original draft, Investigation, Formal analysis, Conceptual-
ization; P.R.J.A.: Writing—Review and editing; Investigation; A.C.: Writing—Review and editing;
Investigation: M.T.: Supervision, Validation; V.C.: Investigation, Resources; R.C.: Investigation,
Resources; P.P.: Supervision, Validation; T.B.: Writing—Original draft, Investigation; Formal analysis;
Conceptualization; ATHERO-APS: Investigation; data collection. All authors have read and agreed
to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Institutional Review Board of Sapienza University of
Rome (Ref: 4417, 2 March 2017).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author. The data are not publicly available due to privacy reasons.
Conflicts of Interest: On behalf of all authors, the corresponding author states that there is no conflict
of interest.
References
1. Pignatelli, P.; Ettorre, E.; Menichelli, D.; Pani, A.; Violi, F.; Pastori, D. Seronegative antiphospholipid syndrome: Refining the
value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica 2020, 105, 562–572. [CrossRef]
2. Serrano, R.; Pons-Estel, G.J.; Espinosa, G.; Quintana, R.M.; Reverter, J.C.; Tassies, D.; Monteagudo, J.; Cervera, R. Long-term
follow-up of antiphospholipid syndrome: Real-life experience from a single center. Lupus 2020, 29, 1050–1059. [CrossRef]
3. Merashli, M.; Ster, I.C.; D’Andrea, G.; Iannaccone, L.; Marottoli, V.; Margaglione, M.; Brancaccio, V.; Ames, P.R.J. Survival in
primary antiphospholipid syndrome. Thromb. Haemost. 2016, 115, 1200–1208. [CrossRef]
4. Radin, M.; Schreiber, K.; Cecchi, I.; Roccatello, D.; Cuadrado, M.J.; Sciascia, S. The risk of ischaemic stroke in primary antiphos-
pholipid syndrome patients: A prospective study. Eur. J. Neurol. 2017, 25, 320–325. [CrossRef]
5. Taraborelli, M.; Reggia, R.; Dall’Ara, F.; Fredi, M.; Andreoli, L.; Gerosa, M.; Hoxha, A.; Massaro, L.; Tonello, M.; Costedoat-
Chalumeau, N.; et al. Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter
Study. J. Rheumatol. 2017, 44, 1165–1172. [CrossRef]
6. Merashli, M.; Bucci, T.; Pastori, D.; Pignatelli, P.; Marottoli, V.; Arcaro, A.; Gentile, F.; Ames, P.R. Antiphospholipid antibodies and
lower extremity peripheral artery disease: A systematic review and meta-analysis. Semin. Arthritis Rheum. 2020, 50, 1291–1298.
[CrossRef]
7. Tufano, A.; Lembo, M.; Di Minno, M.N.; Nardo, A.; Esposito, R.; Santoro, C.; Buonauro, A.; Cerbone, A.M.; Di Minno, G.; Galderisi,
M. Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic
study. Int. J. Cardiol. 2018, 271, 366–370. [CrossRef]
8. Djokovic, A.; Stojanovich, L.; Kontic, M.; Stanisavljevic, N.; Radovanovic, S.; Marisavljevic, D. Association between cardiac
manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary
antiphospholipid syndrome. Isr. Med. Assoc. J. IMAJ 2014, 16, 162–167.
9. Vaccaro, F.; Caccavo, D.; Roumpedaki, E.; De Vincentis, G.; Di Gioia, C.; Gallo, P.; Palange, P. Dilated Cardiomyopathy Due to
Thrombotic Microangiopathy as the only Manifestation of Antiphospholipid Syndrome: A Case Report. Int. J. Immunopathol.
Pharmacol. 2008, 21, 237–241. [CrossRef]
10. Schrage, B.; Geelhoed, B.; Niiranen, T.J.; Gianfagna, F.; Vishram-Nielsen, J.K.K.; Costanzo, S.; Söderberg, S.; Ojeda, F.M.;
Vartiainen, E.; Donati, M.B.; et al. Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting
Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death. J. Am. Heart Assoc. 2020, 9, e015218. [CrossRef]
J. Clin. Med. 2021, 10, 3180 9 of 10
11. Januzzi, J.L.; Rehman, S.U.; Mohammed, A.A.; Bhardwaj, A.; Barajas, L.; Barajas, J.; Kim, H.-N.; Baggish, A.L.; Weiner, R.B.;
Chen-Tournoux, A.; et al. Use of Amino-Terminal Pro–B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients with
Chronic Left Ventricular Systolic Dysfunction. J. Am. Coll. Cardiol. 2011, 58, 1881–1889; [CrossRef]
12. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.;
Jankowska, E.A. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the
diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the
special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016, 18, 891–975.
13. Bhatia, R.S.; Tu, J.; Lee, D.; Austin, P.; Fang, J.; Haouzi, A.; Gong, Y.; Liu, P.P. Outcome of Heart Failure with Preserved Ejection
Fraction in a Population-Based Study. N. Engl. J. Med. 2006, 355, 260–269. [CrossRef]
14. Mc Causland, F.R.; Lefkowitz, M.P.; Claggett, B.; Anavekar, N.S.; Senni, M.; Gori, M.; Jhund, P.C.; McGrath, M.M.; Packer, M.; Shi,
V.; et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction. Circulation
2020, 142, 1236–1245. [CrossRef] [PubMed]
15. Miyakis, S.; Lockshin, M.D.; Atsumi, T.; Branch, D.W.; Brey, R.L.; Cervera, R.; Derksen, R.H.W.M.; De Groot, P.G.; Koike, T.;
Meroni, P.L.; et al. International consensus statement on an update of the classification criteria for definite antiphospholipid
syndrome (APS). J. Thromb. Haemost. 2006, 4, 295–306. [CrossRef]
16. Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbee, E.D.; Hansen,
T.B.; et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Eur. Heart J. 2019, 41, 255–323. [CrossRef]
17. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.;
Dominiczak, A.; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management
of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for
the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.
J. Hypertens 2018, 36, 1953–2041.
18. Knuuti, J.; Wijns, W.; Saraste, A.; Capodanno, D.; Barbato, E.; Funck-Brentano, C.; Prescott, E.; Storey, R.F.; Deaton, C.; Cuisset, T.;
et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis
and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur. Heart J. 2020, 41, 407–477.
[CrossRef]
19. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.;
Kuznetsova, T.; et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the
American society of echocardiography and the European association of cardiovascular imaging. Eur. Heart J. Cardiovasc. Imaging
2015, 16, 233–271. [CrossRef]
20. Pieske, B.; Tschöpe, C.; De Boer, R.A.; Fraser, A.G.; Anker, S.D.; Donal, E.; Edelmann, F.; Fu, M.; Guazzi, M.; Lam, C.S.P.; et al. How
to diagnose heart failure with preserved ejection fraction: The HFA–PEFF diagnostic algorithm: A consensus recommendation
from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 2019, 40, 3297–3317.
[CrossRef]
21. Paulus, W.J.; Tschope, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial
dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013, 62, 263–271.
[CrossRef]
22. Fan, L.; Pan, J.; Lin, H.; Wang, C.; Zhang, J.; Gu, J. Optimal management of blood glucose, blood pressure and atrial fibrillation to
reduce the risk of heart failure with preserved ejection fraction. Intern. Med. J. 2020. [CrossRef]
23. Pastori, D.; Bucci, T.; Triggiani, M.; Ames, P.R.; Parrotto, S.; Violi, F.; Pignatelli, P.; Farcomeni, A. Immunoglobulin G (IgG)
anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis.
Autoimmun. Rev. 2019, 18, 519–525. [CrossRef]
24. Stepien, K.; Nowak, K.; Wypasek, E.; Zalewski, J.; Undas, A. High prevalence of inherited thrombophilia and antiphospholipid
syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. Int. J. Cardiol.
2019, 290, 1–6. [CrossRef] [PubMed]
25. Atsumi, T.; Khamashta, M.A.; Haworth, R.S.; Brooks, G.; Amengual, O.; Ichikawa, K.; Koike, T.; Hughes, G.R.V. Arterial disease
and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis Rheum. 1998, 41, 800–807.
[CrossRef]
26. Merashli, M.; Bucci, T.; Pastori, D.; Pignatelli, P.; Arcaro, A.; Gentile, F.; Marottoli, V.; Ames, P.R. Isoprostanes in systemic lupus
erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. Autoimmun. Rev. 2021, 20, 102821.
[CrossRef] [PubMed]
27. Ames, P.R.; Batuca, J.R.; Ciampa, A.; Iannaccone, L.; Alves, J.D. Clinical relevance of nitric oxide metabolites and nitrative stress
in thrombotic primary antiphospholipid syndrome. J. Rheumatol. 2010, 37, 2523–2530. [CrossRef] [PubMed]
28. Alves, J.D.; Ames, P.R. Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary
antiphospholipid syndrome. Immunobiology 2003, 207, 23–28. [CrossRef]
29. Stanisavljevic, N.; Stojanovich, L.; Marisavljevic, D.; Djokovic, A.; Dopsaj, V.; Kotur-Stevuljevic, J.; Martinovic, J.; Memon, L.;
Radovanovic, S.; Todic, B.; et al. Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome
patients. Clin. Rheumatol. 2016, 35, 2485–2493. [CrossRef]
J. Clin. Med. 2021, 10, 3180 10 of 10
30. Pastori, D.; Pignatelli, P.; Carnevale, R.; Violi, F. Nox-2 up-regulation and platelet activation: Novel insights. Prostaglandins Other
Lipid Mediat. 2015, 120, 50–55. [CrossRef]
31. Weaver, J.C.; Krilis, S.A.; Giannakopoulos, B. Oxidative post-translational modification of betaeta 2-glycoprotein I in the
pathophysiology of the anti-phospholipid syndrome. Free Radic. Biol. Med. 2018, 125, 98–103. [CrossRef]
32. Sciacqua, A.; Borrello, F.; Vatrano, M.; Grembiale, R.D.; Perticone, F. Effect of interaction between left ventricular dysfunction and
endothelial function in hypertension. Curr. Hypertens. Rep. 2006, 8, 212–218. [CrossRef] [PubMed]
33. Corban, M.T.; Duarte-Garcia, A.; McBane, R.D.; Matteson, E.L.; Lerman, L.O.; Lerman, A. Antiphospholipid Syndrome: Role
of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. J. Am. Coll. Cardiol. 2017, 69,
2317–2330. [CrossRef]
34. Sobirin, M.A.; Herry, Y.; Sofia, S.N.; Uddin, I.; Rifqi, S.; Tsutsui, H. Effects of coenzyme Q10 supplementation on diastolic function
in patients with heart failure with preserved ejection fraction. Drug Discov. Ther. 2019, 13, 38–46. [CrossRef]
35. Pérez-Sánchez, C.; Aguirre, M.Á.; Ruiz-Limón, P.; Ábalos-Aguilera, M.C.; Jiménez-Gómez, Y.; Arias-de la Rosa, I.; Rodriguez-
Ariza, A.; Fernández-del Río, L.; González-Reyes, J.A.; Segui, P.; et al. Ubiquinol Effects on Antiphospholipid Syndrome
Prothrombotic Profile: A Randomized, Placebo-Controlled Trial. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 1923–1932. [CrossRef]
36. Ames, P.R.J.; Tommasino, C.; Alves, J.D.; Morrow, J.D.; Iannaccone, L.; Fossati, G.; Caruso, S.; Caccavo, F.; Brancaccio, V.; Ames,
P.R.J.; et al. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: A pilot study. Lupus
2000, 9, 688–695. [CrossRef] [PubMed]
37. Ames, P.R.J.; Merashli, M.; Tommaso, B.; Iannaccone, L.; Marottoli, V.; Ciampa, A. Intensity of immune/clotting assays relate
to multiple antiphospholipid antibody positivity in thrombotic primary antiphospholipid syndrome. Int. J. Hematol. 2021, 113,
183–189. [CrossRef] [PubMed]
38. Pengo, V.; Ruffatti, A.; Legnani, C.; Gresele, P.; Barcellona, D.; Erba, N.; Testa, S.; Marongiu, F.; Bison, E.; Denas, G.; et al. Clinical
course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 2010, 8, 237–242. [CrossRef]
39. Zuily, S.; Clerc-Urmès, I.; Bauman, C.; Andrade, D.; Sciascia, S.; Pengo, V.; Tektonidou, M.G.; Ugarte, A.; Gerosa, M.; Belmont,
H.M.; et al. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from
the APS ACTION Registry. Lupus 2020, 29. [CrossRef] [PubMed]
40. Sciascia, S.; Radin, M.; Cecchi, I.; Levy, R.A.; Erkan, D. 16th International congress on antiphospholipid antibodies task force
report on clinical manifestations of antiphospholipid syndrome. Lupus 2021, 30, 1314–1326. [CrossRef]
